ADDYY, ADDDF EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages adidas AG Investors to Inquire About Securities Class Action Investigation – ADDYY, ADDDF

NEW YORK, Feb. 15, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of adidas AG (OTC: ADDYY, ADDDF) resulting from allegations that adidas may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Adidas securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit–form/?case_id=12204 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On October 25, 2022, Adidas ended its lucrative business partnership with Kanye West (under which it sold shoes designed by West under the brand name "Yeezy") as a result of his anti–Semitic rhetoric.

On November 27, 2022, The Wall Street Journal published an article entitled "Adidas Top Executives Discussed Risk of Staff's "Direct Exposure' to Kanye West Years Ago." According to the article, as early as 2018, adidas executives discussed ending the business partnership with West as a result of his behavior. Reportedly adidas feared continuing the relationship with West, as they feared it could "blow up" at any moment. The article added that West made anti–Semitic statements in front of adidas staff, and that he told adidas staff that he was considering naming an album after Adolf Hitler.

On February 9, 2023 adidas announced that "while the company continues to review future options for the utilization of its Yeezy inventory, this guidance already accounts for the significant adverse impact from not selling the existing stock. This would lower revenues by around 1.2 billion and operating profit by around 500 million this year." Further, "should the company irrevocably decide not to repurpose any of the existing Yeezy product going forward, this would result in the write–off of the existing Yeezy inventory and would lower the company's operating profit by an additional 500 million this year. In addition, adidas expects one–off costs of up to 200 million in 2023. These costs are part of a strategic review the company is currently conducting aimed at reigniting profitable growth as of 2024. If all these effects were to materialize, the company would expect to report an operating loss of 700 million in 2023." adidas' CEO stated, "[t]he numbers speak for themselves. We are currently not performing the way we should[.]"

As a result of these adverse disclosures the price of Adidas securities have fallen, damaging investors.

A class action lawsuit is being prepared by The Rosen Law Firm. Please go to https://rosenlegal.com/submit–form/?case_id=12204 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com to join the prospective case.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8750180)

Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

  • Type D meeting protocol submission builds on concurrence reached with FDA following successful Type C meeting and supports potential Phase 3 initiation in H2 2023

JERUSALEM, Feb. 15, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced that a Type D meeting protocol review has been accepted by the U.S. Food and Drug Administration (FDA) to provide responses by March 30th, 2023. The pivotal, Phase 3 study protocol is entitled "A 24–Month Phase 3, Randomized, Double–Blind, Global Multicenter Study Comparing the Effects of Oral hPTH(1–34) (EBP05[EB613]) Daily Tablets vs. Placebo on Bone Mineral Density (BMD) in Postmenopausal Women with Osteoporosis." EB613 is the first oral, once daily mini tablet presentation of hPTH (1–34), (teriparatide). EB613 has a well–established mechanism of action, PK and safety profile and met primary (PD/biomarker) and secondary endpoints (BMD) in a placebo controlled, dose ranging Phase 2 study in 161 postmenopausal women with low bone mass and osteoporosis.

As part of its briefing documents for the Type D process, Entera has submitted its Phase 3 protocol which reflects (1) the agreement reached during the Company's September 2022 Type C Meeting discussion with FDA that a single 24 month Phase 3 placebo–controlled study could support a New Drug Application (NDA) submission under the 505(b)(2) regulatory pathway and (2) that Total Hip Bone Mineral Density (BMD) could serve as the primary endpoint for the registrational study. The objective of Type D meeting review is to confirm that the protocol fully meets FDA's expectations, including the analysis of the primary endpoint and the population PK evaluations, ahead of potential study initiation in H2 2023.

The FDA previously agreed on major design elements of the protocol including the primary endpoint, enrollment criteria, titration and 2:1 randomization plan, and that 400 or more patients on EB613 is consistent with ICH E1A to support safety for the NDA. The current protocol reflects a 667/333 patient randomization, a 24 month total study duration and a futility interim analysis to occur when the last of the 300 first randomized subjects have completed 12 months in the study. Furthermore, Entera has provided power calculations for its primary endpoint, the change in TH BMD vs. placebo and for its key secondary endpoint which is designed to evaluate the change in TH BMD versus published surrogate threshold effects (STEs) that are associated with fracture risk reduction (Eastell 2022i).

"We look forward to continuing our incredibly collaborative dialogue with the FDA concerning what we anticipate as the last critical step prior to potentially initiating our Phase 3 pivotal study in H2 2023. Since receiving FDA's End of Phase 2 minutes in January of 2022 which conveyed that the previously anticipated non–inferiority head–to–head design versus Forteo Phase 3 design may not be favorable to the approvability of our program, the Company has undergone a massive leadership and operational shift to successfully pivot and align with FDA's recommendations and transition to become Phase 3 ready. To our knowledge, Entera stands as the first osteoporosis drug development company ever permitted to conduct a single placebo controlled registrational study with a BMD (NOT fracture) endpoint. This is unprecedented and we believe, speaks to the agency's partnership in this journey to find a viable treatment alternative to treat the millions of osteoporosis patients that, despite the guidelines and availability of highly efficacious anabolic agents, are simply unwilling to take the daily or monthly injections," stated Miranda Toledano, Chief Executive Officer of Entera.

About Entera Bio

Entera is a leader in the development of orally delivered macromolecules, including peptides and other therapeutic proteins. The Company focuses on significant unmet medical needs where a simple, oral mini–tablet peptide replacement therapy holds the potential to transform the standard of care. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism, are in clinical development. EB613 is the first oral, once daily mini tablet presentation of synthetic hPTH (1–34), (teriparatide), consisting of the exact same 34 amino acid sequence as daily subcutaneous teriparatide injection, Forteo which has been the leading anabolic treatment of osteoporosis since 2002 with peak sales of $1.7 billion in 2018 prior to patent expiration. A placebo controlled, dose ranging Phase 2 study of EB613 mini–tablets (n= 161) met primary (PD/biomarker) and secondary endpoints (BMD). In October 2022, the Company announced concurrence with FDA on a single, placebo controlled, BMD endpoint pivotal study design to support an NDA for EB613 tablets. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.

Cautionary Statement Regarding Forward Looking Statements

Various statements in this press release are "forward–looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward–looking statements. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera's forward–looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA's interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera is contractually obligated to provide, such as those pursuant to Entera's agreement with Amgen; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera's product candidates; Entera's reliance on third parties to conduct its clinical trials; Entera's expectations regarding licensing, business transactions and strategic collaborations; Entera's operation as a development stage company with limited operating history; Entera's ability to continue as a going concern absent access to sources of liquidity; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the "Cautionary Statements Regarding Forward–Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Entera's most recent Annual Report on Form 10–K filed with the SEC, as well as the company's subsequently filed Quarterly Reports on Form 10–Q and Current Reports on Form 8–K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward–looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward–looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

___________________

i Eastell R, Vittinghoff E, Lui LY, et al. Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH–ASBMR SABRE Project. J Bone Miner Res. 2022;37(1):29–35.


GLOBENEWSWIRE (Distribution ID 8750087)

Cellebrite Announces Fourth Quarter 2022 Results

ARR of $249 million, up 33% year–over–year

Fourth–quarter revenue of $74.0 million, Increase 9% year–over–year

Fourth–quarter adjusted EBITDA of $16.1 million, 21.8% adjusted EBITDA margin

PETAH TIKVA, Israel and TYSONS CORNER, Va., Feb. 15, 2023 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in Digital Intelligence ("DI") solutions for the public and private sectors, today announced financial results for the three and twelve months ending December 31, 2022.

"We ended 2022 with solid quarterly results fueled by our industry–leading technology in a healthy Digital Intelligence market. Our market leadership remains strong as a result of the tangible progress and investments we have made in innovating across our platforms and executing on our go–to–market strategy," said Yossi Carmil, Cellebrite's CEO. "As data volumes are surging, data complexity is increasing and scrutiny around ethics and accountability are mounting, we are committed to helping customers modernize their investigations by digitizing the evidence workflows end–to–end. We enter 2023 well positioned to accelerate our revenue growth rate and drive improved profitability as we continue to capitalize on the strong demand we see for our offerings."

Fourth Quarter Financial Highlights

  • Annual Recurring Revenue (ARR) of $249 million, up 33% year–over–year
  • Revenue of $74.0 million, up 9% year–over–year, of which subscription revenue was $62.3 million, up 24% year–over–year
  • Recurring revenue dollar–based net retention rate of 130%
  • GAAP gross profit and gross margin of $61.9 million and 83.6%, respectively
  • GAAP net income of $7.1 million; Non–GAAP net income of $15.3 million
  • GAAP diluted EPS of $0.04; Non–GAAP diluted EPS of $0.08
  • Adjusted EBITDA and adjusted EBITDA margin of $16.1 million and 21.8%, respectively

Full Year Financial Highlights

  • Revenue of $270.7 million, up 10% year–over–year, of which subscription revenue was $216.0 million, up 18% year–over–year
  • GAAP gross profit and gross margin of $219.9 million and 81.3%, respectively
  • GAAP net income of $120.8 million; Non–GAAP net income of $19.7 million
  • Adjusted EBITDA and Adjusted EBITDA margin of $25.9 million and 10%, respectively

Fourth Quarter and Recent Digital Intelligence Highlights

  • Closed 29 large deals in the fourth quarter, each valued at $500,000 or more.
  • Won a $14 million agreement with a leading law enforcement agency in Asia for the company's Advanced Extraction Solution.
  • Signed a $10+ million deal with a major West European national police force, marking one of the Company's largest digital intelligence deals, further validating digital intelligence as an essential accelerator for investigators.
  • Announced that its collaboration with the Vanderburgh Co. Cyber Crime Task Force to service 29 agencies across 11 U.S. states has helped accelerate justice by reducing the time it takes to investigate and successfully prosecute felonies.
  • Launched new cloud workplace app collection capability for Cellebrite Endpoint Inspectorthataims to improve organizations' investigation and eDiscovery capabilities. Thisnew functionalitywill enable customers to collect remote mobile and computer data as well as cloud workplace application data in one unified platform, reducing time and costs associated with the collection of data of these apps.
  • Published the Enterprise Solutions 2023 Industry Trends Report, which highlights major data collection headaches arising from a hybrid work environment that threaten to slow down corporate fraud, IP theft and sexual harassment investigations for eDiscovery professionals and corporate investigators.
  • Partnered with the Gangmasters and Labour Abuse Authority (GLAA), and The Exodus Road to help these organizations advance their efforts to advance their respective missions and eliminate forced labor and human trafficking.

Supplemental financial information can be found on the Investor Relations section of our website at https://investors.cellebrite.com/financial–information/quarterly–results.

Financial Outlook

"With a strong 33% annual growth in ARR during 2022 and 84% of our fourth–quarter 2022 revenue coming from subscription software licenses, Cellebrite has largely completed a successful, multi–year transition to subscription software," said Dana Gerner, Chief Financial Officer of Cellebrite. "Looking ahead, we are well positioned to increase our revenue growth rate and sustain solid ARR momentum in 2023 as we continue expanding wallet share with existing customers, complemented by winning new logos. We anticipate that the combination of our top–line growth and prudent investment in our operations will enable us to drive improvement in our profitability during 2023, and keep us on track to reach our original long–term EBITDA margin target of 20% or greater."

  • December 2023 ARR is expected to be between $300 and $310 million, representing 21–25% year on year growth.
  • Full year 2023 revenue is expected to be between $305 and $315 million, representing 13–16% year on year growth.
  • Full year 2023 Adjusted EBITDA is expected to be between $35.0 and $40.0 million, representing 11–13% margin.

Conference Call Information
Today, February 15, 2023, at 8:30 a.m. ET, Cellebrite will host a conference call and webcast to discuss the Company's financial results for the fourth quarter 2022. The call details are below:

Telephone participants are advised to register in advance at:
https://register.vevent.com/register/BIa98ecd8f02c04567a1515497e1f850c8.

Upon registration, participants will receive a confirmation email detailing how to join the conference call, including the dial–in number and a unique registrant ID.

The live conference call will be webcast in listen–only mode at: https://edge.media–server.com/mmc/p/6j7zngzy.

The webcast will remain available after the call at: https://investors.cellebrite.com/events–presentations

Non–GAAP Financial Information

This press release includes non–GAAP financial measures. Cellebrite believes that the use of non–GAAP net income, non–GAAP operating income and Adjusted EBITDA is helpful to investors. These measures, which the Company refers to as our non–GAAP financial measures, are not prepared in accordance with GAAP.

The Company believes that the non–GAAP financial measures provide a more meaningful comparison of its operational performance from period to period and offers investors and management greater visibility to the underlying performance of its business. Mainly:

  • Share–based compensation expenses utilize varying available valuation methodologies, subjective assumptions and a variety of equity instruments that can impact a company's non–cash expenses;
  • Acquired intangible assets are valued at the time of acquisition and are amortized over an estimated useful life after the acquisition, and acquisition–related expenses are unrelated to current operations and neither are comparable to the prior period nor predictive of future results;
  • To the extent that the above adjustments have an effect on tax (income) expense, such an effect is excluded in the non–GAAP adjustment to net income;
  • Tax expense, depreciation and amortization expense vary for many reasons that are often unrelated to our underlying performance and make period–to–period comparisons more challenging; and
  • Financial instruments are remeasured according to GAAP and vary for many reasons that are often unrelated to the Company's current operations and affect financial income.

Each of our non–GAAP financial measures is an important tool for financial and operational decision making and for evaluating our own operating results over different periods of time. The non–GAAP financial measures do not represent our financial performance under U.S. GAAP and should not be considered as alternatives to operating income or net income or any other performance measures derived in accordance with GAAP. Non–GAAP measures should not be considered in isolated from, or as an alternative to, financial measures determined in accordance with GAAP. Non–GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non–GAAP financial results differently, particularly related to non–recurring, unusual items. In addition, there are limitations in using non–GAAP financial measures because the non–GAAP financial measures are not prepared in accordance with GAAP, and exclude expenses that may have a material impact on our reported financial results. Further, share–based compensation expense has been, and will continue to be for the foreseeable future, significant recurring expenses in our business and an important part of the compensation provided to our employees. In addition, the amortization of intangible assets is expected recurring expense over the estimated useful life of the underlying intangible asset and acquisition–related expenses will be incurred to the extent acquisitions are made in the future. Furthermore, foreign exchange rates may fluctuate from one period to another, and the Company does not estimate movements in foreign currencies.

A reconciliation of each of these non–GAAP financial measures to their most comparable GAAP measure is set forth in a table included at the end of this press release, which is also available on our website at https://investors.cellebrite.com.

Key Performance Indicators

This press release also includes key performance indicators, including annual recurring revenue and dollar–based retention rate.

Annual recurring revenue ("ARR") is defined as the annualized value of active term–based subscription license contracts and maintenance contracts related to perpetual licenses in effect at the end of that period. Term–based license contracts and maintenance contracts for perpetual licenses are annualized by multiplying the revenue of the last month of the period by 12. The annualized value of contracts is a legal and contractual determination made by assessing the contractual terms with our customers. The annualized value of maintenance contracts is not determined by reference to historical revenue, deferred revenue or any other GAAP financial measure over any period. ARR is not a forecast of future revenues, which can be impacted by contract start and end dates and renewal rates.

Dollar–based net retention rate ("NRR") is calculated by dividing customer recurring revenue by base revenue. We define base revenue as recurring revenue we recognized from all customers with a valid license at the last quarter of the previous year period, during the four quarters ended one year prior to the date of measurement. We define our customer revenue as the recurring revenue we recognized during the four quarters ended on the date of measurement from the same customer base included in our measure of base revenue, including recurring revenue resulting from additional sales to those customers.

About Cellebrite

Cellebrite's (NASDAQ: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite's Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more, visit us at www.cellebrite.com and https://investors.cellebrite.com.

Caution Regarding Forward Looking Statements

This document includes "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "will," "appear," "approximate," "foresee," "might," "possible," "potential," "believe," "could," "predict," "should," "could," "continue," "expect," "estimate," "may," "plan," "outlook," "future" and "project" and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward looking statements include estimated financial information. Such forward looking statements with respect to revenues, earnings, performance, strategies, prospects, and other aspects of Cellebrite's business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward looking statements. These factors include, but are not limited to: Cellebrite's ability to keep pace with technological advances and evolving industry standards; Cellebrite's material dependence on the acceptance of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite's DI solutions; Cellebrite's failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; uncertainties regarding the impact of macroeconomic and/or global conditions, including COVID–19 and military actions involving Russia and Ukraine; intense competition in all of Cellebrite's markets; the inadvertent or deliberate misuse of Cellebrite's solutions; political and reputational factors related to Cellebrite's business or operations; risks relating to estimates of market opportunity and forecasts of market growth; Cellebrite's ability to properly manage its growth; risks associated with Cellebrite's credit facilities and liquidity; Cellebrite's reliance on third–party suppliers for certain components, products, or services; challenges associated with large transactions and long sales cycle; risks that Cellebrite's customers may fail to honor contractual or payment obligations; risks associated with a significant amount of Cellebrite's business coming from government customers around the world; risks related to Cellebrite's intellectual property; security vulnerabilities or defects, including cyber–attacks, information technology system breaches, failures or disruptions; the mishandling or perceived mishandling of sensitive or confidential information; the complex and changing regulatory environments relating to Cellebrite's operations and solutions; the regulatory constraints to which we are subject; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite's shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite's significant international operations; risks associated with Cellebrite's failure to comply with anti–corruption, trade compliance, anti–money–laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite's existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite's current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled "Risk Factors" in Cellebrite's annual report on Form 20–F filed with the SEC on March 29, 2022,as amended on April 14, 2022 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission ("SEC"), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Contacts:

Investors
Investor Relations
investors@cellebrite.com

Media
Victor Cooper
Public Relations and Corporate Communications Director
+1 404 804 5910
Victor.cooper@cellebrite.com

Cellebrite DI Ltd.
Fourth Quarter 2022 Results Summary
(U.S Dollars in thousands)

For the three months ended For the Year ended
December 31, December 31,
2022 2021 2022 2021
Revenue 74,018 67,908 270,651 246,246
Gross profit 61,887 55,572 219,905 203,689
Gross margin 83.6 % 81.8 % 81.3 % 82.7 %
Operating income 9,674 4,306 1,044 13,822
Operating margin 13.1 % 6.3 % 0.4 % 5.6 %
Cash flow from operating activities 35,743 29,792 20,577 36,052
Non–GAAP Financial Data:
Operating income 14,428 7,751 19,538 42,869
Operating margin 19.5 % 11.4 % 7.2 % 17.4 %
Adjusted EBITDA 16,114 8,874 25,906 47,905
Adjusted EBITDA margin 21.8 % 13.1 % 9.6 % 19.5 %


Cellebrite DI Ltd.
Condensed Consolidated Balance Sheets
(U.S. Dollars in thousands)

December 31, December 31,
2022 2021
Assets
Current assets
Cash and cash equivalents $ 87,645 $ 145,973
Short–term deposits 51,335 35,592
Marketable securities 44,643 ""
Trade receivables (net of allowance for doubtful accounts of $1,904 and $1,040 as of December 31, 2022 and 2021, respectively) 78,761 67,505
Prepaid expenses and other current assets 17,085 12,818
Contract acquisition costs 6,286 4,813
Inventories 10,176 6,511
Total current assets 295,931 273,212
Non–current assets
Other non–current assets 1,731 1,958
Marketable securities 22,125 ""
Deferred tax assets, net 12,511 9,800
Property and equipment, net 17,259 16,756
Intangible assets, net 11,254 11,228
Goodwill 26,829 26,829
Operating lease right–of–use assets, net 15,653 ""
Total non–current assets 107,362 66,571
Total assets $ 403,293 $ 339,783
Liabilities and shareholders' equity (deficiency)
Current Liabilities
Trade payables $ 4,612 $ 9,546
Other accounts payable and accrued expenses 45,453 54,044
Deferred revenues 152,709 122,983
Operating lease liabilities 5,003 ""
Total current liabilities 207,777 186,573
Long–term liabilities
Other long term liabilities 5,394 9,537
Deferred revenues 42,173 36,426
Restricted Sponsor Shares liability 17,532 44,712
Price Adjustment Shares liability 26,184 79,404
Warrant liability 20,015 56,478
Operating lease liabilities 10,353 ""
Total long–term liabilities 121,651 226,557
Total liabilities $ 329,428 $ 413,130
Shareholders' equity (deficiency)
Share capital *) *)
Additional paid–in capital (125,624 ) (153,072 )
Treasury share, NIS 0.00001 par value; 41,776 ordinary shares (85 ) (85 )
Accumulated other comprehensive income 331 1,372
Retained earnings 199,243 78,438
Total shareholders' equity (deficiency) 73,865 (73,347 )
Total liabilities and shareholders' equity (deficiency) $ 403,293 $ 339,783

*) Less than 1 USD



Cellebrite DI Ltd.
Condensed Consolidated Statements of Income
(U.S Dollars in thousands, except share and per share data)

For the three months ended For the Year ended
December 31, December 31,
2022 2021 2022 2021
Revenue:
Subscription services $ 43,698 $ 31,999 $ 153,470 $ 120,889
Term–license 18,625 18,088 62,487 62,428
Total subscription 62,323 50,087 215,957 183,317
Perpetual license and related 3,666 9,387 21,373 34,169
Professional services 8,029 8,434 33,321 28,760
Total revenue 74,018 67,908 270,651 246,246
Cost of revenue:
Subscription services 3,681 2,045 16,875 9,369
Term–license 50 753 425 2,299
Total subscription 3,731 2,798 17,300 11,668
Perpetual license and related 3,381 4,659 12,987 9,817
Professional services 5,019 4,879 20,459 21,072
Total cost of revenue 12,131 12,336 50,746 42,557
Gross profit $ 61,887 $ 55,572 $ 219,905 $ 203,689
Operating expenses:
Research and development 19,734 18,833 80,620 65,541
Sales and marketing 23,669 21,239 97,387 76,389
General and administrative 8,810 11,194 40,854 47,937
Total operating expenses $ 52,213 $ 51,266 $ 218,861 $ 189,867
Operating income $ 9,674 $ 4,306 $ 1,044 $ 13,822
Financial (expense) income, net (572 ) 49,809 119,716 68,483
Income before tax 9,102 54,115 120,760 82,305
Tax expense (income) 2,024 2,244 (45 ) 10,909
Net income $ 7,078 $ 51,871 $ 120,805 $ 71,396
Earnings per share
Basic $ 0.04 $ 0.28 $ 0.64 $ 0.49
Diluted $ 0.04 $ 0.25 $ 0.59 $ 0.44
Weighted average shares outstanding
Basic 184,952,107 180,170,342 182,693,375 144,002,394
Diluted 192,786,615 199,082,479 195,393,558 161,538,579
Other comprehensive income:
Unrealized income (loss) on hedging transactions 1,194 495 (953 ) (944 )
Unrealized income (loss) on marketable securities 44 "" (502 ) ""
Currency translation adjustments (133 ) 955 414 995
Total other comprehensive income (loss) net of tax 1,105 1,450 (1,041 ) 51
Total other comprehensive income $ 8,183 $ 53,321 $ 119,764 $ 71,447


Cellebrite DI Ltd.
Condensed Consolidated Statements of Cash Flow
(U.S Dollars in thousands, except share and per share data)

For the three months ended For the Year ended
December 31, December 31,
2022 2021 2022 2021
Cash flow from operating activities:
Net income $ 7,078 $ 51,871 $ 120,805 $ 71,396
Adjustments to reconcile net income to net cash provided by operating activities:
Share based compensation and RSU's 3,787 1,661 13,708 6,480
Amortization of premium, discount and accrued interest on marketable securities (225 ) "" (372 )
Depreciation and amortization 2,520 1,814 9,194 7,007
Interest income from short term deposits (318 ) "" (684 ) ""
Deferred income taxes (61 ) 269 (2,392 ) (1,638 )
Remeasurement of warrant liability 375 (15,506 ) (36,463 ) (11,967 )
Remeasurement of Restricted Sponsor Shares 1,381 (11,181 ) (27,180 ) (17,635 )
Remeasurement of Price Adjustment Shares liabilities 1,211 (23,934 ) (53,220 ) (38,271 )
Decrease (increase) in trade receivables 11,242 8,690 (12,885 ) (1,958 )
Increase in deferred revenue 18,953 9,152 38,966 21,804
Decrease (increase) in other non–current assets 94 (1,779 ) 227 (1,394 )
(Increase) decrease in prepaid expenses and other current assets (4,431 ) 2,541 (5,692 ) (8,304 )
Changes in operating lease assets 4,667 "" 4,667 ""
Changes in operating lease liability (5,955 ) "" (5,955 ) ""
Increase in inventories (812 ) (1,711 ) (3,680 ) (1,798 )
(Decrease) increase in trade payables (895 ) 2,955 (5,471 ) 4,239
(Decrease) increase in other accounts payable and accrued expenses (2,060 ) 2,428 (8,853 ) 5,107
(Decrease) increase in other long–term liabilities (808 ) 2,522 (4,143 ) 2,984
Net cash provided by operating activities 35,743 29,792 20,577 36,052
Cash flows from investing activities:
Purchases of property and equipment (1,391 ) (778 ) (6,897 ) (5,111 )
Cash paid in conjunction with acquisitions, net of acquired cash "" (20,000 ) "" (20,000 )
Purchase of Intangible assets (1,788 ) "" (2,188 ) ""
Investment in marketable securities (9,253 ) "" (89,364 ) ""
Proceeds from maturity of marketable securities 7,445 "" 22,277 ""
Assets acquisition "" "" "" (3,000 )
Investment in short term deposits (51,000 ) (21,000 ) (76,000 ) (21,000 )
Redemption of short term deposits 18,544 47,210 60,941 94,337
Net cash (used in) provided by investing activities (37,443 ) 5,432 (91,231 ) 45,226
Cash flows from financing activities:
Payment of dividend "" "" "" (100,000 )
Exercise of options to shares 1,327 944 12,628 2,305
Proceeds from Employee Share Purchase Plan, net 657 "" 1,337 ""
Exercise of public warrants "" "" 5 ""
Proceeds from Recapitalization transaction, net "" "" "" 29,298
Net cash provided by (used in) financing activities 1,984 944 13,970 (68,397 )
Net increase (decrease) in cash and cash equivalents 284 36,168 (56,684 ) 12,881
Net effect of Currency Translation on cash and cash equivalents 2,795 (81 ) (1,644 ) (754 )
Cash and cash equivalents at beginning of period 84,566 109,886 145,973 133,846
Cash and cash equivalents at end of period $ 87,645 $ 145,973 $ 87,645 $ 145,973
Supplemental cash flow information:
Income taxes paid $ 3,727 $ 1,758 $ 9,053 $ 8,157
Non–cash activities
Purchase of property and equipment $ "" $ 749 $ "" $ 814
Purchase of Intangible assets $ 493 $ "" $ 664 $ ""


Cellebrite DI Ltd.

Reconciliation of GAAP to Non–GAAP Financial Information
(U.S Dollars in thousands, except share and per share data)

For the three months ended For the year ended
December 31, December 31,
2022 2021 2022 2021
Unaudited Unaudited Unaudited Unaudited
Operating income $ 9,674 $ 4,306 $ 1,044 $ 13,822
Issuance expenses "" "" "" 11,835
Dividend participation compensation "" "" "" 966
Share based compensation 3,787 1,661 13,708 6,480
Amortization of intangible assets 834 607 2,826 1,971
Acquisition related costs 133 1,177 1,960 7,795
Non–GAAP operating income $ 14,428 $ 7,751 $ 19,538 $ 42,869
For the three months ended For the year ended
December 31, December 31,
2022 2021 2022 2021
Unaudited Unaudited Unaudited Unaudited
Net income $ 7,078 $ 51,871 $ 120,805 $ 71,396
One time tax (income) expense "" "" (2,368 ) 7,067
Issuance expenses "" "" "" 11,835
Dividend participation compensation "" "" "" 966
Share based compensation 3,787 1,661 13,708 6,480
Amortization of intangible assets 834 607 2,826 1,971
Acquisition related costs 133 1,177 1,960 7,795
Tax expense (income) 516 498 (384 ) (1,670 )
Finance expense (income) from financial derivatives 2,967 (50,621 ) (116,863 ) (67,873 )
Non–GAAP net income $ 15,315 $ 5,193 $ 19,684 $ 37,967
Non–GAAP Earnings per share:
Basic 0.08 $ 0.03 0.10 $ 0.26
Diluted 0.08 $ 0.03 0.10 $ 0.24
Weighted average shares outstanding:
Basic 184,952,107 180,170,342 182,693,375 144,002,394
Diluted 192,786,615 199,082,479 195,393,558 161,538,579

For the three months ended For the year ended
December 31, December 31,
2022 2021 2022 2021
Unaudited Unaudited Unaudited Unaudited
Net income $ 7,078 $ 51,871 $ 120,805 $ 71,396
Financial expense (income), net 572 (49,809 ) (119,716 ) (68,483 )
Tax expense (income) 2,024 2,244 (45 ) 10,909
Issuance expenses "" "" "" 11,835
Dividend participation compensation "" "" "" 966
Share based compensation 3,787 1,661 13,708 6,480
Amortization of intangible assets 834 607 2,826 1,971
Acquisition related costs 133 1,177 1,960 7,795
Depreciation expenses 1,686 1,123 6,368 5,036
Adjusted EBITDA $ 16,114 $ 8,874 $ 25,906 $ 47,905


GLOBENEWSWIRE (Distribution ID 8749609)

How the Privatization of Eletrobras May Lead To an Uncertain Future in Brazil’s Energy Transition and Favor Price Increase to the End-Consumer

Brazil’s then-President Jair Bolsonaro launched the sale of shares of Eletrobras, the largest company in the electricity sector in Brazil, which will be privatized through its capitalization. CREDIT: Alan Santos/PR-Public Photos

By Victoria Barreto Vieira do Prado
NEW YORK, Feb 15 2023 – Eletrobras is Latin America’s biggest electricity company, responsible for around 30% of Brazil’s power capacity and 50% of all its transmission lines. In 2021, the Brazilian government announced it would reduce its controlling shares in this state-owned company from 72% to 10%.  Given Eletrobras’ dominant role in Brazil’s power sector, this divestment in the government’s controlling shares merits a more complete understanding of the implications for Brazil’s energy transition and energy security.

This is because the law that was passed to make this happen raises important risks to the decarbonization of the country’s power sector and has the potential to increase electricity tariffs.

 

How the legal process that open the door for the government’s controlling stake on Eletrobras raised questions about the energy transition

The government’s dilution of its participation as Eletrobras’ major shareholder required legal approval in congress, consolidated through a law now commonly known as Eletrobras’ privatization law (Law 14.182/2021).

Of all the amendments to the Eletrobras’ privatization law, the mandatory installation of 8 GW of additional thermal gas power capacity to be deployed between 2026 and 2030 was perhaps the most troublesome. To understand how massive this is, this provision in theory forces Brazil to expand natural gas installed capacity by 56%

Given how politically charged this law is and the electoral dynamics due to looming presidential elections in the following year (2022), the government decided to fast-track this bill in congress under a mechanism known as a provisional measure (medida provisória), thus expediting its approval process. The deadline for approval of bills using this fast-track provision is of 120 days.

While an effective legislative tool, the use of this fast-track provision in this law was criticized by some institutions in Brazil as not “conducive to the timeframe required to conduct a comprehensive study” that the privatization of a company like Eletrobras would have merited.

The bill was approved on the eve of the fast-track deadline for its approval. However, it contained over 500 amendments, many of which were unrelated to the company’s privatization.

This strategy is known as jabuti, where legislators take advantage of the provisional measure’s fast-paced characteristics to include amendments which may favor their own political interests. By adding amendments to key clauses of the bill, as was done in Eletrobras’ privatization, the likelihood of vetoing the added amendments is close to null.

Of all the amendments to the Eletrobras’ privatization law, the mandatory installation of 8 GW of additional thermal gas power capacity to be deployed between 2026 and 2030 was perhaps the most troublesome. To understand how massive this is, this provision in theory forces Brazil to expand natural gas installed capacity by 56% per cent from around 14.3 GW in 2021.

While this measure gave no responsibility to Eletrobras for the deployment of this thermal capacity, it signals the government’s direction and ambition for the power sector. In addition, this amendment included a provision that the new thermal power plants had to function constantly for 70% of the time throughout the next 15 years.

Such mandatory use for thermal in the future, would result if followed through, in an expected 33% increase of greenhouse gas emissions and redraw the country’s electricity matrix which is currently one of the cleanest globally with 82.9% renewables (world average being 28.6%).

The law, as approved today, also disfavors renewable sources, currently the cheapest form of energy in Brazil, which have no additional variable costs of operation to fuel the power grid.

The new law requirements may increase installation costs by up to R$ 6.6 billon (roughly USD 1.3 billion) when compared to the prior Brazilian national energy expansion strategy and thus reflect in price increases for the end-consumer. A requirement to operate the thermal powerplants for 70% of the time has negative implications for the future development of non-hydropower renewables given that it reduces wind and solar power capacity expansion in up to 12 GW and 3.5 GW until 2030, respectively.

The law does not significantly affect hydropower capacity expansion (already projected to slow down), which would increase modestly in about 0.2 GW in the same time frame and remain responsible for one of the largest shares of the Brazilian power mix.

 

The impact of this build up in thermal power in Brazil

The inclusion of gas-powered plants is supposed to address energy security and support the company’s efficiency in providing reliable energy nationwide as frequent droughts threaten hydropower capacity. While understandable as an objective, as it stands, the current provisions are problematic in many fronts, not only in terms of the GHG emission implications.

According to the law’s provisions, the mandatory regions where these thermal powerplants are to be installed are mostly in water-abundant regions. Second the natural gas infrastructure is lacking. Third, additional infrastructure investments may lead to higher energy prices for the end-consumer.

Gas feeding these power plants will mostly come from Brazil’s southeast region to be transported across the country, which adds to transportation costs and emissions. Through this lens, the government-issued Ten-Year Energy Plan (PDE 2031) acknowledges the difficulty and costs of implementation due to the necessary added infrastructure requirements. The report implies that meeting the mandated targets may be challenging. This was reflected in October 2022 auctions in which 1.17 GW of additional capacity for gas-powered power plants were contracted at a price seven times higher than those bided at similar auctions in previous years.

In addition, the implementation of new powerplants would require decades of on-going operation to ensure full amortization of costs. This may lead to stranded assets as demand for cleaner sources of energies outpace fossil fuels. Although the government has claimed that part of the additional installed capacity will be used to replace existing thermal power plants (to be switched off by 2024), emissions from additional infrastructure and the 70% intermittency requirement outpace the efficiency gains from the new installations.

This is reinforced when added to the additional requirement of developing 721 kilometers of transmission lines in the Amazon Rainforest region, 125 kilometers of which are located in indigenous land. This implies additional infrastructure costs and more emissions (linked to deforestation). Equally difficult is that such buildup of infrastructure in the Amazon Rainforest and disregard to social and environmental licenses infringes on Brazil’s Sustainable Development Goals, thus also going against national energy planning.

 

Even if it is in the law, will Brazil’s be able to attract capital for natural gas power plants?

While technically enforceable by the Eletrobras’ law, many questions remain on whether companies will be willing to invest in capital-intensive projects which may soon become stranded – especially when penalties for doing otherwise remain unclear.

In addition, it is unlikely that Eletrobras’ new shareholders would be on board with such a massive of buildout in thermal power plants. Singapore’s sovereign fund, GIC; Canadian pension fund, CPPIB; and, Brazilian Investment Management company, 3G Radar, each hold around 11% of Eletrobras.

All of these financial actors have shown considerable interests towards investing in the energy transition and decarbonizing their portfolios. It is thus believed that this could hinder their willingness in investing in high-cost gas power plants which require additional infrastructure investments in order to become profitable, not to mention that Brazil does not produce enough natural gas and thus might need to be imported via very expensive LNG.

Regardless, if the additional capacity of 8 GW of thermal gas power does go through, one should expect these power plants to be running for a considerably long time in order to fully amortize the investments. This could lead to a 33% emission increase which will slow down the Brazilian government’s energy transition strategy.

Lula, Brazil’s new president, has indicated that its government will revise this 8 GW mandate, an attempt to remove the 70% inflexibility requirement. Instead, the new government might make the additional power as back-up for renewable energy intermittence, diminishing the potential environmental hinderance foreseen in the law. In order to do so, a new motion would have to be approved in congress – a usually time-intensive measure. This regulatory uncertainty may in the meantime decrease energy investments and impact the pace of the energy transition.

 

The Eletrobras law also pushed for renewables

The Eletrobras law did promote measures which favor the energy transition. However, if all these requirements are fulfilled, they may also increase electricity prices for the end consumers.

The law dictated new concessions for hydropower generation for the next 30 years, ensuring dispatchable renewable energy, which contributes to the country’s energy transition. However, it favors hydropower plants which fall under the price quota regime, allowing them to sell the generated electricity under market prices rather than through imposed limits by the national electricity agency (ANEEL). This may lead to higher tariff prices, which could reach R$ 167/MWh in 2051 (compared to R$ 93/MWh today). The government tried to curtail this by mandating that half of the revenue generated through Eletrobras’ privatization shall be directed to diminishing the tariff increase. Despite this measure, this could still represent up to eight times less than the required investment needed to keep prices low.

An additional measure promotes the development of small hydropower plants, to be developed over the next 20 years. While this promotes dispatchable renewable energy and addresses the need to replace existing old hydro powerplants which would soon cease operations, it also favors the most expensive form of renewable energy available, again creating possible cost impacts for the end-consumer. The government addressed this by creating a price cap according to 2019 auction prices adjusted to inflation (R$ 314.55 / MWh). These prices remain 7.7% higher than those found in 2021 auctions.

The government also included the extension of PROINFA by 20 years. PROINFA is a governmental program established between 2002 and 2022 which created subsidies for biomass and small hydro power plants, wind, and solar farm owners in order to incentivize the production of renewable energy sources in the country.

While positive in theory, such extension would only favor previous contracts as opposed to a structural revision of the Brazilian power grid and costs of renewable technologies. Most of these investments have already been amortized and cost of technology has decreased significantly.

Its impact in promoting the energy transition therefore, can be questioned, as it is not necessarily deploying new renewable technologies, but rather favoring outdated contracts at higher costs. A more interesting alternative instead would have been to promote the expansion of new low-cost renewable energy projects through new auctions.

 

Final thoughts: The Mixed Outcome of Electrobras’ privatization Law

In conclusion, it is unclear what impact will Eletrobras’ privatization truly incur for the country’s energy transition. It is argued that through its privatization, the company will now be freed from bureaucracy, allowing it to speed up investments and increase its ability to invest in new (riskier) clean technologies.

Eletrobras’ CEO, has been known for his inclination towards green technologies and has advocated for green hydrogen investments in several occasions. The same is expected from the new shareholders, who have been seen to adopt decarbonization investment strategies. Eletrobras’ net zero strategies across scope 1, 2, and 3 are also contradictory to exactly the amendments of the law, claiming to decarbonize through the sales of thermal-powered power plants and I-REC purchases.

However, it is important to note that the law does push for thermal gas expansion, which, if occurs, may shift and delay Brazil’s energy transition. The absence of clear penalizations and accountability makes it unclear on whether the additional capacity of 8 GW of thermal gas powerplants will indeed be adopted.

While it is unclear how much the privatization will truly impact the energy transition, increase in tariff prices may be likely. The law and the subsequent auctions since its approval, seem to favor costly renewable contracts, which will likely increase tariffs for the end-consumer. Tariff increases may also happen due to the expansion of PROINFA, promotion of small hydro power plants, and implied cost of necessary added infrastructure for thermal gas-powered plants.

 

Victoria Barreto Vieira do Prado is a MSc. Sustainability Management student at Columbia University. Prior to her studies, she has worked in the development of the Brazilian Voluntary Carbon Market via her work at Carbonext, and in the decarbonization strategies of major players in the Brazilian hard-to-abate sectors as a consultant

 

References

ANEEEL. (2022)(A). Três usinas a gás natural são licitadas em Leilão de Reserva de Capacidade. Gov.br. Retrieved October 30th.

ANEEEL. (2022)(B). Resultados do Leilão – LEILÃO DE GERAÇÃO ANEEL Nº 008/2022 – Resumo Vendedor 02° LEILÃO DE RESERVA DE CAPACIDADE – ENERGIA. Epe.br. Retrieved Janyary 7th

CCEE. (2022). Resultados Leilão ANEEL Outubro 2022. CCEE. Retrieved from November 1st

Eletrobras (2022)(A). Apresentação de resultados 2T22. RI Eletrobras. Retrieved October 24th, 2022

Eletrobras (2022)(B). Estretatégica Climática. Portal Eletrobras. Retrieved January 7th, 2023

Empresa de Pesquisa Energética; Ministério de Minas e Energia. (2022). Plano Decenal de Expansão de Energia. Gov.br. Retrieved October 25th

Epbr. (2022). Primeiro leilão de térmicas da MP da Eletrobras não interioriza o gás. PSE Unicamp. Retrieved October, 30th, 2022

Instituto Escolhas; Escopo Energia. (August 2021). Relatório desestatização da Eletrobras: Impactos no planejamento do setor elétrico. Escolhas.org. Retrieved October 24th, 2022

Ministério de Minas e Energia. (2022). Visão do MME sobre os impactos da capitalização da Eletrobras. Gov.br. Retrieved October, 30th, 2022

Pamplona, Nicola. (2022). Eletrobras decide sair de carvão e desmobilizar térmicas mais poluentes. Folha de S. Paulo. Retrieved January, 7th, 2023

Ramalho, André. (2022). Tolmasquim defende térmicas flexíveis e vê renováveis como soft power para o Brasil. Epbr. Retrieved January 7th, 2023

República Federativa do Brasil. (2021). Lei Nº 14.182, de 12 de julho de 2021. Diário Oficial da União. Retrieved October 25th, 2022

Tomalsquim, Mauricio. (2022). Proposta de Privatização da Eletrobras e seus desdobramentos para o Setor Elétrico Brasileiro. PSE Unicamp. Retrieved October, 30th, 2022

World Leaders, Private Sector Urged to Establish an International Green Bank to Win Climate Change Battle

A family take shelter on the roof of their small house. Due to climate change, incessant rainfall has flooded nearby houses. The photo was taken from Jatrapur Union in Kurigram District. Credit: Muhammad Amdad Hossain/Climate Visuals

A family take shelter on the roof of their small house. Due to climate change, incessant rainfall has flooded nearby houses. The photo was taken from Jatrapur Union in Kurigram District. Credit: Muhammad Amdad Hossain/Climate Visuals

By Joyce Chimbi
NAIROBI, Feb 15 2023 – As the effects of climate change escalate and natural disasters such as earthquakes, floods, and droughts become more frequent and severe, threatening lives and livelihoods, humanity is losing the climate battle.

A sharp decline in the variety and the number of both wild animals and species, severe food insecurities, high levels of malnutrition, disappearing streams, springs, and rivers in some areas, and dangerous rises in sea levels that threaten island nations are alerting the world to a climate-driven catastrophe.

Yet even as the world stares at unprecedented climate disasters, experts such as Hafez Ghanem caution that existing international institutions are not delivering on climate change mitigation and finance and are now calling for renewed efforts through the establishment of a Green Bank.

Hafez Ghanem says the creation of a Green Bank to solely address climate change adaptation and mitigation efforts is long overdue.

Hafez Ghanem says the creation of a Green Bank to solely address climate change adaptation and mitigation efforts is long overdue.

Ghanem, former regional Vice President of the World Bank Group and a current nonresident senior fellow in the Global Economy and Development Program at the Brookings Institution, Senior Fellow at the Policy Center for the New South, and Distinguished Fellow at the Paris School of Economics tells IPS that “the creation of a Green Bank as a new international institution to solely address climate change adaptation and mitigation efforts is long overdue.”

“Everybody is looking at how to finance investments in climate change. The estimate is that USD 2 trillion is needed every year for countries in the global South alone to address climate change.”

Today’s development assistance, he says, is about USD 200 billion per year, “so we need to multiply that figure 10-fold and only use the funds for climate change and forget about critical social sectors such as health and education.”

Choosing the climate agenda over critical social sectors or vice-versa is a lose-lose situation because they are both matters of life and death. This has led world leaders to a critical crossroads.

To meet the climate financing gaps, Ghanem says many of the developed countries are asking existing multilateral development banks, such as the World Bank, to reform and invest more in climate change.

Ghanem says reforms within existing institutions will not work and recommends a different approach: the establishment of a singular international institution that concerns itself solely with climate-related matters. An institution that would be a repository for global knowledge on climate change and advice governments on climate policies.

He says a Green Bank would also develop green projects across the Global South and support their financing and implementation. As currently constituted, multilateral development banks are yet to open up space for Global South to be heard at the same level as those in the North.

At the World Bank, for instance, he says, the voting power is such that the G7 countries control 39.8 percent of the World Bank while other donors control another 14.9 percent.

“Despite the World Bank conducting most of its business in Africa, the largest ten African countries control only about 3.5 percent of its voting power. A development bank that is controlled by its borrowers is not a good idea; neither is a development bank where beneficiaries feel that they don’t have enough voice,” he expounds.

A waterfall is on the verge of drying out. High temperatures and prolonged droughts are blamed on the devastating impact of climate change. Credit: Joyce Chimbi/IPS

A waterfall is on the verge of drying out. High temperatures and prolonged droughts are blamed on the devastating impact of climate change. Credit: Joyce Chimbi/IPS

Ghanem further emphasizes that the absence of the private sector will continue to curtail efforts to raise much-needed funds. “I believe that the Green Bank should be a public-private partnership where private corporations, foundations, and civil society organizations are invited to participate in its capital together with sovereign states.   I am calling for a tripartite approach where countries of the Global South have the same voice, same voting rights as those in the Global North and the private sector.”

The need to attract much-needed funds from the private sector cannot be over-emphasized, he says as it is now, “there is no voice from the private sector because the owners of, say, the World Bank and the African Development Bank are all sovereign states.”

The Green Bank would, therefore, primarily support private green investments through equity contributions, loans, and guarantees at the national, regional, or global level. The new institution would also free existing multilateral banks to direct scarce resources to social and development assistance.

This would significantly boost progress toward the delivery of critical social sectors services such as health and education, particularly in poorer, more vulnerable nations such as those classified as Least Developed Countries.

As such, the proposed Green Bank will not be in competition or opposition to existing multilateral banks but an instrument to partner with other institutions and complement their projects.

“Climate change is an external threat facing all of humanity, and all of humanity needs to unite to face it. But a major share of humanity and particularly the Global South lacks the necessary resources,” he says.

“There are many international meetings and summits at which resources are pledged, but the pledges are for much less than what is needed to deal with climate change. Moreover, not all pledges materialize as actual commitments and disbursements.”

As governments in the Global North face tighter budget constraints and competing interests, limiting their ability to provide much-needed finance for climate projects in the South even as climate catastrophes increase, Ghanem says a new approach in the form of a Green Bank that is a private, public partnership would be an important contribution to the solution.  You can read his full policy brief on the subject here.

IPS UN Bureau Report

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

China and Russia Fail to Defund UN Human Rights Work

UN Human Rights Council meeting in Geneva

By Louis Charbonneau
NEW YORK, Feb 15 2023 – United Nations member states agreed to fully fund UN human rights mechanisms that China, Russia, and their allies had sought to defund in the 2023 budget. This should set a precedent for UN human rights funding in the future.

Human Rights Watch has warned for years about China and Russia-led efforts to slash funding for UN human rights work, which was aimed at undermining decisions by the UN Human Rights Council, General Assembly, and Security Council.

During the General Assembly’s budget negotiations in late 2022, China, Russia and allies proposed a resolution to defund human rights investigations in Sri Lanka, Iran, Venezuela, Russia, Ukraine, Nicaragua, North Korea, Belarus, Syria, and Eritrea. Ethiopia proposed a resolution to defund an investigation of war crimes and abuses in Ethiopia itself.

Israel also urged states to deny funding for an International Court of Justice advisory opinion on the legal consequences of its 55-year occupation of Palestinian territory.

All these efforts failed. The Czech Republic, as European Union president, countered by proposing full funding for human rights mechanisms at the level proposed by Secretary-General António Guterres. The resolution passed by a sizable majority.

There’s more good news. Not only did the defunding efforts fail, the highly problematic recommendations put forward by the UN Advisory Committee on Administrative and Budgetary Questions (ACABQ) were rejected.

The Advisory Committee is supposed to be an independent body of experts, but in recent years, its “experts” from countries like China and Russia have been pushing their governments’ anti-human rights agendas and advocating for sharp cuts in funding for human rights work, with no good reasons.

Due to divisions between Western countries and developing states, the standard UN funding compromise had become accepting the non-binding Advisory Committee recommendations. For example, if its recommendations had been adopted, the staff and budget for the Iran commission of inquiry would have been cut in half.

UN member countries should treat the successful UN budget outcome as a blueprint for the future. The job of the Fifth Committee – which oversees UN budget matters – is to allocate resources, not question mandates approved by UN legislative bodies.

They should also reform or replace the Advisory Committee on Administrative and Budgetary Questions with an advisory body staffed by genuinely independent experts, not diplomats doing the bidding of their governments.

Meanwhile, UN delegations should build on this success and ensure reliable full funding for all UN human rights mandates.

Louis Charbonneau is UN Director Human Rights Watch

IPS UN Bureau

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);